001448601 000__ 05602cam\a2200553\a\4500
001448601 001__ 1448601
001448601 003__ OCoLC
001448601 005__ 20230310004247.0
001448601 006__ m\\\\\o\\d\\\\\\\\
001448601 007__ cr\un\nnnunnun
001448601 008__ 220806s2022\\\\si\\\\\\o\\\\\000\0\eng\d
001448601 019__ $$a1337925533
001448601 020__ $$a9789811692321$$q(electronic bk.)
001448601 020__ $$a9811692327$$q(electronic bk.)
001448601 020__ $$z9811692319
001448601 020__ $$z9789811692314
001448601 0247_ $$a10.1007/978-981-16-9232-1$$2doi
001448601 035__ $$aSP(OCoLC)1338837959
001448601 040__ $$aEBLCP$$beng$$epn$$cEBLCP$$dGW5XE$$dYDX$$dEBLCP$$dOCLCQ$$dOCLCF$$dOCLCQ
001448601 049__ $$aISEA
001448601 050_4 $$aRS420
001448601 08204 $$a615.1/9$$223/eng/20220809
001448601 24500 $$aBiomedical translational research :$$bdrug design and discovery /$$cR.C. Sobti, Naranjan S. Dhalla, editors.
001448601 260__ $$aSingapore :$$bSpringer,$$c2022.
001448601 300__ $$a1 online resource (597 pages)
001448601 336__ $$atext$$btxt$$2rdacontent
001448601 337__ $$acomputer$$bc$$2rdamedia
001448601 338__ $$aonline resource$$bcr$$2rdacarrier
001448601 500__ $$a5.3.3.2 Cystic Fibrosis
001448601 5050_ $$aIntro -- Preface -- Contents -- About the Editors -- Part I: Basic Aspects -- 1: Emerging Technologies: Gateway to Understand Molecular Insight of Diseases, Newer Drugs, Their Design, and Targeting -- 1.1 Introduction -- 1.2 Advanced Technologies for Control of Infectious Diseases -- 1.3 Role of Artificial Intelligence (AI) in Epidemiology -- 1.4 Drug Discovery-Associated Technologies -- 1.5 Speedy Drug Discovery with Artificial Intelligence (AI) and Machine Learning -- 1.6 How Do AI Platforms Work? -- 1.7 Heading Toward Precision Medicines (PM) Through Innovation and New Technologies
001448601 5058_ $$a1.8 Summary and Conclusion -- References -- 2: Polypharmacology: New Paradigms in Drug Development -- 2.1 Introduction -- 2.2 Polypharmacology Studies Using In Silico Approaches -- 2.2.1 Ligand-Based Methods -- 2.2.2 Similarity Search Based on 2D and 3D Descriptors -- 2.2.3 Structure-Based Methods -- 2.2.4 Inverse Docking -- 2.2.5 Multi-Target Drug Design (MTDD) -- 2.2.6 Multi-Target Virtual Ligand Screening (VLS) -- 2.3 Data Mining to Identify Novel Targets from ``Big Data:́́ A Network Systems Biology Approach -- 2.4 Drug Repurposing -- 2.5 Concluding Remarks -- References
001448601 5058_ $$a3: Drug Repurposing in Biomedical Research: Benefits and Challenges -- 3.1 Introduction -- 3.2 Benefits Associated with Drug Repositioning -- 3.3 Challenges Associated with Drug Repositioning -- 3.4 Drug Repositioning Intended for Anticancer Applications -- 3.4.1 Itraconazole -- 3.4.2 Digoxin -- 3.4.3 Nitroxoline -- 3.5 Drug Repurposing for RNA Virus Infections -- 3.5.1 ZIKV and Other Flaviviruses -- 3.5.2 Ebola Virus -- 3.5.3 Coronaviruses -- 3.5.4 Influenza Virus -- 3.6 Drug Repurposing for DNA Virus Infections -- 3.7 Potential Drugs for Repurposing Against Infectious Agents
001448601 5058_ $$a3.7.1 Anticancer Drugs Repurposed Against Bacteria and Fungi -- 3.7.2 Immunomodulatory Drugs Repurposed Against Bacteria and Fungi -- 3.8 Concluding Remarks -- References -- 4: Computational Methods for Drug Repurposing -- 4.1 Historical -- 4.2 Introduction -- 4.2.1 Protein-Protein Interactions -- 4.2.2 Pathway Databases -- 4.2.3 Drug-Target Interactions -- 4.2.4 Genetic Variation and Disease-Gene Interactions -- 4.2.5 Drug Induced Gene Expression Signatures -- 4.3 Major Techniques of Drug Repurposing -- 4.3.1 Connectivity Map -- 4.3.2 Side Effect Similarity -- 4.3.3 Network-Based Approach
001448601 5058_ $$a4.3.4 Chemical Similarity -- 4.4 Summary -- References -- 5: Genomic Approaches for Drug Repositioning -- 5.1 Introduction -- 5.2 Experimental and In Silico Approaches to DR -- 5.2.1 Experimental Approaches -- 5.2.2 In Silico Approaches -- 5.3 Genomic Approaches to DR -- 5.3.1 Linking Target Genes to Clinically Approved Drugs -- 5.3.2 Usage of Computational Methods -- 5.3.2.1 Genome-Wide Association Studies (GWAS) -- 5.3.2.2 Network-Based Approaches and the Support of Artificial Intelligence (AI) -- 5.3.3 Examples of DR for Genetic Diseases -- 5.3.3.1 Alzheimerś Disease
001448601 506__ $$aAccess limited to authorized users.
001448601 520__ $$aThis book, which is the third volume of Biomedical translational research, focuses on the fundamental role of biomedical research in developing new medicinal products. It emphasizes the importance of understanding biological and pathophysiological mechanisms underlying the disease to discover and develop new biological agents. The book uniquely explores the genomic computational integrative approach for drug repositioning. Further, it discusses the health benefits of nutraceuticals and their application in human diseases. Further, the book comprehensively reviews different computational approaches that employ GWAS data to guide drug repositioning. Finally, it summarizes the major challenges in drug development and the strategies for the rational design of the next generation more effective but less toxic therapeutic agents.
001448601 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed August 9, 2022).
001448601 650_0 $$aDrugs$$xDesign$$xResearch.
001448601 650_0 $$aBiomedical engineering$$xResearch.
001448601 655_0 $$aElectronic books.
001448601 7001_ $$aSobti, R. C.
001448601 7001_ $$aDhalla, Naranjan S.
001448601 77608 $$iPrint version:$$aSobti, R.C.$$tBiomedical Translational Research.$$dSingapore : Springer, ©2022$$z9789811692314
001448601 852__ $$bebk
001448601 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-16-9232-1$$zOnline Access$$91397441.1
001448601 909CO $$ooai:library.usi.edu:1448601$$pGLOBAL_SET
001448601 980__ $$aBIB
001448601 980__ $$aEBOOK
001448601 982__ $$aEbook
001448601 983__ $$aOnline
001448601 994__ $$a92$$bISE